Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells target Hard-to-Treat lung cancer in early trial

NCT ID NCT07116057

Recruiting now Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 24 times

Summary

This early-phase trial tests a new treatment for people with a specific type of advanced lung cancer (FRa+ NSCLC) that has spread to the lining around the lungs. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells, then given as a single dose into the chest cavity. The main goals are to check if the treatment is safe and feasible, and to see if it can shrink tumors. Only 10 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT LUNG NON-SMALL CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC NON-SMALL CELL LUNG CANCER RECURRENT LUNG NON-SMALL CELL CARCINOMA